PRLD Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates 9 hours ago **BREAKING: Prelude Therapeutics Reports Wider-Than-Expected Q4 Loss** Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M 9 hours ago Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially.